Sarepta Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Preliminary phase I/II data for SRP-1001 (FSHD) and SRP-1003 (DM1) show robust, dose-dependent muscle delivery, strong gene knockdown, and favorable safety profiles. Both programs plan to advance to phase III in 2027, with more MAD data expected later this year.
-
Revenue guidance for 2026 remains strong, with ELEVIDYS and PMO franchises supported by robust clinical data and ongoing sales force expansion. Key clinical milestones for DM1, FSHD, and nonambulant ELEVIDYS are on track, while pivotal trials and manufacturing scale-up are targeted for 2027.
-
Three-year results from the EMBARK Phase 3 trial show ELEVIDYS provides sustained, statistically significant slowing of Duchenne progression, with treated patients maintaining motor function and experiencing fewer losses of ambulation compared to controls. No new safety signals emerged, and benefits appear to widen over time.
-
Strong financial performance in 2025 sets the stage for growth in 2026, with Elevidys and PMOs driving revenue and a robust siRNA pipeline advancing. Enhanced safety measures, regulatory progress, and newborn screening initiatives are expected to expand market reach.
Fiscal Year 2025
-
Entered 2026 with strong financials, $2.2B 2025 revenue, and $954M cash. ELEVIDYS and PMO franchises remain stable, with new educational initiatives expected to drive 2026 revenue of $1.2–$1.4B. CEO to retire by end of 2026; robust pipeline and Japan launch support future growth.
-
Q3 revenues reached $399M, with strong PMO and ELEVIDYS sales despite shipment disruptions. ESSENCE trial for VYONDYS and AMONDYS showed clinical benefit trends but missed statistical significance, impacted by COVID-19. Financials improved via cost cuts, debt restructuring, and positive cash flow.
-
A fatal adverse event in a completed LGMD 2D trial was disclosed, with no impact on the known safety profile or regulatory status of Elevidys. Shipments for nonambulatory patients remain paused, and the FDA has not changed its position. Strategic focus has shifted to siRNA, with only SRP-9003 advancing.
-
A second non-ambulatory patient death from acute liver failure after Elevidys led to a pause in dosing and commercial shipments for this group. Preclinical data support adding sirolimus to mitigate risk, and protocol amendments are being pursued with FDA input. Revenue guidance is suspended pending further updates.
-
The meeting covered board and executive introductions, confirmed a quorum, and approved all five proposals, including director elections, executive compensation, equity plan amendments, and auditor ratification. A Q&A session followed for stakeholder engagement.
-
Q1 revenue grew 70% year-over-year, but guidance was lowered due to a safety event, longer therapy initiation times, and site capacity constraints. Regulatory progress continues, with key pipeline milestones and approvals expected through 2028. Financial strength supports ongoing operations and pipeline advancement.
-
Q1 2025 saw 70% net product revenue growth, led by ELEVIDYS, but guidance was revised to $2.3–$2.6B due to a safety event, administrative delays, and site capacity constraints. Cash remains strong, and a recovery is expected in the second half of the year.
-
Two-year EMBARK data show Elevidys provides sustained, statistically significant functional benefits and muscle health preservation in Duchenne patients, with a favorable safety profile and no loss of ambulation. Early treatment is emphasized, and the results are expected to support global regulatory and payer discussions.
-
Record revenue growth in 2024 was driven by Elevidys, the most successful gene therapy launch to date, with robust guidance for 2025 and a strong late-stage pipeline. Expansion efforts, new siRNA programs, and operational excellence position the company for sustained growth.
Fiscal Year 2024
-
ELEVIDYS drove record revenue growth in 2024, with net product revenue up 56% year-over-year and Q4 sales exceeding guidance. 2025 guidance projects 70% growth, led by ELEVIDYS, and the pipeline expanded with the Arrowhead acquisition.
-
Q3 2024 saw 39% revenue growth year-over-year, driven by Elevidys and a strong PMO franchise, with profitability achieved on both GAAP and non-GAAP bases. The company discontinued its PPMO program, advanced late-stage LGMD trials, and reiterated guidance for $3B revenue in 2025.
-
ELEVIDYS achieved a broad label and strong launch, driving significant revenue growth and broad patient access. Manufacturing and supply are robust, with future scalability planned. Pipeline and business development efforts target further expansion, with a focus on rare and genetic diseases.
-
Q2 2024 revenue grew 51% year-over-year to $362.9M, driven by expanded ELEVIDYS approval and robust demand. 2025 revenue guidance is $2.9–$3.1B, with strong growth expected in Q4 as the broader label adoption accelerates. Cash flow turned positive, and long-term outlook remains strong.
-
ELEVIDYS received expanded FDA approval for Duchenne patients aged 4 and older, with strong clinical evidence and no near-term supply constraints. Pricing remains unchanged, supported by cost-effectiveness data, and broad site readiness ensures immediate access. Ongoing studies aim to further expand eligibility and confirm long-term benefits.
-
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals approved by shareholders. No additional proposals were introduced, and no questions were raised during the Q&A session.